Operating
Benefit from Receivables
Johnson & Johnson Benefit from Receivables increased by 11.1% to -$8.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from -$4.00M to -$8.00M. Over 2 years (FY 2022 to FY 2024), Benefit from Receivables shows an upward trend with a -19.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2007
Last reportedQ1 2026Apr 22, 2026
Metric ID:
csco_benefit_from_receivablesHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$39.00M | -$8.00M | $6.00M | -$9.00M | -$11.00M | -$3.00M | $1.00M | -$1.00M | $0.00 | $0.00 | $0.00 | $0.00 | -$11.00M | $22.00M | -$4.00M | $7.00M | -$9.00M | -$8.00M |
| QoQ Change | — | +79.5% | +175.0% | -250.0% | -22.2% | +72.7% | +133.3% | -200.0% | +100.0% | — | — | — | — | +300.0% | -118.2% | +275.0% | -228.6% | +11.1% |
| YoY Change | — | — | — | +76.9% | -37.5% | — | -83.3% | +88.9% | +100.0% | +100.0% | -100.0% | +100.0% | — | — | — | — | +18.2% | -100.0% |
Range-$39.00M – $22.00M
CAGR-31.1%
Avg YoY Growth+16.3%
Median YoY Growth+47.6%
Benefit from Receivables at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's benefit from receivables?
- Johnson & Johnson (JNJ) reported benefit from receivables of -$8.00M in Q1 2026.
- How has Johnson & Johnson's benefit from receivables changed year-over-year?
- Johnson & Johnson's benefit from receivables decreased by 100.0% year-over-year, from -$4.00M to -$8.00M.
- What is the long-term trend for Johnson & Johnson's benefit from receivables?
- Over 2 years (2022 to 2024), Johnson & Johnson's benefit from receivables has grown at a -19.6% compound annual growth rate (CAGR), from -$17.00M to $11.00M.